ADVERSE EVENTS IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING LIPOSOMAL IRINOTECAN: UNDERSTANDING THE OCCURRENCE AND HOW MANAGEMENT AFFECTS PATIENT OUTCOMES

被引：0
|
作者：
Jameson, Gayle [1 ]
Caldwell, Lana [1 ]
Mirakhur, Beloo [2 ]
de Jong, Floris [3 ]
Ansaldo, Karen [1 ]
机构：
[1] HonorHealth, Scottsdale, AZ USA
[2] Ipsen Biopharmaceut, Basking Ridge, NJ USA
[3] Shire GmbH, Zug, Switzerland
来源：
ONCOLOGY NURSING FORUM | 2018年 / 45卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS-15
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
    Lim, Huezin H.
    Hopkins, Ashley M.
    Rowland, Andrew
    Yuen, Hoi Y.
    Karapetis, Christos S.
    Sorich, Michael J.
    TARGETED ONCOLOGY, 2019, 14 (06) : 743 - 748
  • [32] VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5fluoroucil and leucovorin in the Czech Republic
    Batko, S.
    Vocka, M.
    Duchonova, B. M.
    Liberko, M.
    Majkova, P.
    Buchler, T.
    Petruzelka, L. B.
    Melichar, B.
    Soumarova, R.
    Hejduk, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S919 - S919
  • [33] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Management of Enzalutamide Related Adverse Events for Castration Resistant Prostate Cancer by Patient Reported Outcomes
    Iguchi, Taro
    Yasuda, Sayaka
    Kato, Minoru
    Yamazaki, Takeshi
    Tamada, Satoshi
    Nakatani, Tatsuya
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil.
    Kortmansky, JS
    Sauter, N
    O'Reilly, E
    Shah, M
    Abou-Alfa, GK
    Winkelman, J
    Yi, S
    Gonen, M
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 162S - 162S
  • [36] Machine learning based prediction of serious adverse events in metastatic breast cancer patients receiving zoledronic acid
    Tanni, Kaniz Afroz
    Qian, Jingjing
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 568 - 568
  • [37] Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States
    Cockrum, Paul
    Surinach, Andy
    Kim, George P.
    Mercer, Daniel
    Koeller, Jim M.
    Miksad, Rebecca A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] Improving the management of patients with pancreatic cancer: Education from treatment to adverse events and coordination of care
    Parikh, K.
    Cameron, D.
    Van Laar, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S163 - S163
  • [39] Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (03) : 427 - 435
  • [40] Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
    Tang, Cheng-Yu
    Yang, Shih-Hung
    Li, Chung-Pin
    Su, Yung-Yeh
    Chiu, Sz-Chi
    Bai, Li-Yuan
    Shan, Yan-Shen
    Chen, Li-Tzong
    Chuang, Shih-Chang
    Chan, De-Chuan
    Yen, Chia-Jui
    Peng, Cheng-Ming
    Chiu, Tai-Jan
    Chen, Yen-Yang
    Chen, Jen-Shi
    Chiang, Nai-Jung
    Chou, Wen-Chi
    PANCREATOLOGY, 2024, 24 (03) : 600 - 607
12345